PCI Mandates Aadhaar-Based Attendance System For Staff

New Delhi:  The Pharmacy Council of India (PCI) has announced a phased implementation of the Aadhaar Enabled Biometric Attendance System (AEBAS) in all PCI-approved pharmacy institutions, starting from the 2025-2026 academic session. This system aims to monitor attendance for faculty and non-faculty staff. This circular was issuedon January 24, 2025.

The AEBAS will be rolled out in phases, with the first phase focusing on attendance monitoring for all staff.

Action Items for Institutions

All institutions must acquire STQC-certified biometric authentication devices by February 23, 2025.

Institutions need to share details of the installed devices with valid QR codes on the SIF Application (DigiPHARMed Portal) along with signed and sealed invoices.

Procurement must adhere to the STQC-certified device specifications outlined in Appendix D of the AEBAS Guidelines.

Wall-mounted devices are preferred for most employees. USB fingerprint scanners or IRIS scanners with Windows 7/8 desktops can be used for senior staff or specific sections. Alternatives like wall-mounted iris scan or face recognition devices can be used only if fingerprint authentication fails.

Institutions must purchase enough devices to guarantee daily attendance recording for all staff.

Institutions are responsible for procuring, installing, and configuring devices directly from vendors. They should ensure detailed terms and conditions for after-sales support.

A stable internet connection is crucial for the system’s functionality. Institutions are responsible for maintaining sufficient AEBAS devices with Wi-Fi or fiber optic internet connectivity. Consistent biometric data capture is essential, and the PCI will take action for gaps exceeding 3 working days without justification.

PCI Responsibilities

The PCI will not handle communication regarding device maintenance issues. Furthermore, the PCI will provide further instructions for implementing the attendance monitoring system in due course.

This notification emphasizes the importance of immediate action for pharmacy institutions. Strict compliance is mandatory. Institutions must prioritize acquiring the required devices, ensuring proper internet connectivity, and maintaining a smooth data capture process.

SOURCE : Legality Simplified

Related Posts

CPHI Milan launches four special AI, cold chain, contamination control & labelling zones at this year’s event

Milan: CPHI Milan 2026, one of the pharmaceutical industry’s largest global events, has launched four specialist zones designed to connect pharmaceutical companies with the technologies, services and expertise shaping the…

Lilly takes 6 companies to court for selling retatrutide knockoffs

Washington: Eli Lilly’s experimental weight-loss drug retatrutide has yet to be approved by the FDA. But the buzz surrounding the effectiveness of the compound—commonly known as triple-G—has already triggered a…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

CPHI Milan launches four special AI, cold chain, contamination control & labelling zones at this year’s event

CPHI Milan launches four special AI, cold chain, contamination control & labelling zones at this year’s event

Lilly takes 6 companies to court for selling retatrutide knockoffs

Lilly takes 6 companies to court for selling retatrutide knockoffs

FDA Busts Abortion Medicine Racket in Nagpur, Solapur; IndiaMART Directors among 8 Booked

FDA Busts Abortion Medicine Racket in Nagpur, Solapur; IndiaMART Directors among 8 Booked

Gleneagles BGS Hospital honours donor families with India’s largest organ donation recognition wall

Gleneagles BGS Hospital honours donor families with India’s largest organ donation recognition wall

NCB Uncovers Pharmaceutical Fentanyl Diversion Racket in Rural Punjab; Over 18,000 NDPS Drug Units Seized

NCB Uncovers Pharmaceutical Fentanyl Diversion Racket in Rural Punjab; Over 18,000 NDPS Drug Units Seized

Sun Pharma will Need HC Nod for Semaglutide Tablet Launch

Sun Pharma will Need HC Nod for Semaglutide Tablet Launch